Research Article
Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome
Table 1
Demographic data and incidence rates of selected diseases.
| | Characteristic | All patients () | 1 injection () | 3 injections () |
() | | % | | % | | % |
| | Sex (number male) | 42 | 61.8 | 17 | 58.6 | 25 | 64.1 | 0.212 | | Diagnosed with hypertension | 43 | 63.2 | 17 | 58.6 | 26 | 66.7 | 0.496 | | Diagnosed with diabetes | 27 | 39.7 | 12 | 41.1 | 15 | 38.5 | 0.808 | | Diagnosed with hypercoagulability | 1 | 1.5 | 1 | 3.4 | 0 | 0 | | | Age: mean (range) | 68.0 (29–83) | | 63.5 (29–79) | | 63.4 (49–83) | | 0.890 | | Baseline visual acuity (Mean) | 6/90 | | 6/85 | | 6/95 | | 0.963 |
|
|
